📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. (2019)

First Author: Gupta V

Attributed to: Unravelling biological heterogeneity in neoplastic myeloproliferative stem cells funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.bbmt.2018.09.001

PubMed Identifier: 30205231

Publication URI: http://europepmc.org/abstract/MED/30205231

Type: Journal Article/Review

Volume: 25

Parent Publication: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

Issue: 2

ISSN: 1083-8791